Branch² Intelligence
FTSE 100 held back by AstraZeneca trial setback
Key takeaway
AstraZeneca trial setback drags FTSE 100 down 16.59 points.
- Step 1AstraZeneca trial setback reduces expected future cash flows from the drug candidate.
- Step 2Lower valuation and risk-off sentiment depress FTSE 100 index, increasing equity risk premium.
- Step 3Higher equity risk premium may spill over to corporate bond spreads, raising SME financing costs.
Source: The Independent Business
This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.